Beijing Hotgen Biotech Co Ltd - Asset Resilience Ratio
Beijing Hotgen Biotech Co Ltd (688068) has an Asset Resilience Ratio of 20.87% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 688068 current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2024)
This chart shows how Beijing Hotgen Biotech Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Beijing Hotgen Biotech Co Ltd assets under control.
Liquid Assets Composition Over Time
This chart breaks down Beijing Hotgen Biotech Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read 688068 total liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥669.32 Million | 20.87% |
| Total Liquid Assets | CN¥669.32 Million | 20.87% |
Asset Resilience Insights
- Good Liquidity Position: Beijing Hotgen Biotech Co Ltd maintains a healthy 20.87% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Beijing Hotgen Biotech Co Ltd Industry Peers by Asset Resilience Ratio
Compare Beijing Hotgen Biotech Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Abivax SA
PA:ABVX |
Biotechnology | 2.58% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Lifecome Biochemistry Co Ltd
SHE:002868 |
Biotechnology | 4.69% |
|
Pulike Biological Engineering
SHG:603566 |
Biotechnology | 17.82% |
|
Rocket Pharmaceuticals Inc
NASDAQ:RCKT |
Biotechnology | 14.00% |
|
NEWRON PHARMACEUT. EO-20
XETRA:NP5 |
Biotechnology | 41.67% |
|
Upstream Bio, Inc.
NASDAQ:UPB |
Biotechnology | 64.70% |
Annual Asset Resilience Ratio for Beijing Hotgen Biotech Co Ltd (2021–2024)
The table below shows the annual Asset Resilience Ratio data for Beijing Hotgen Biotech Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 6.06% | CN¥201.51 Million ≈ $29.49 Million |
CN¥3.33 Billion ≈ $486.68 Million |
-1.81pp |
| 2023-12-31 | 7.86% | CN¥280.02 Million ≈ $40.98 Million |
CN¥3.56 Billion ≈ $521.03 Million |
-14.93pp |
| 2022-12-31 | 22.79% | CN¥888.68 Million ≈ $130.04 Million |
CN¥3.90 Billion ≈ $570.59 Million |
-2.65pp |
| 2021-12-31 | 25.45% | CN¥927.45 Million ≈ $135.71 Million |
CN¥3.64 Billion ≈ $533.36 Million |
-- |
About Beijing Hotgen Biotech Co Ltd
Beijing Hotgen Biotech Co., Ltd. engages in the research, development, manufacture, and sale of medical and public safety inspection products of in-vitro diagnostic products in the field of biomedicine. It offers public safety solutions such as drug tasting, customs disease control, bioterrorism and food safety solutions. The company also provides clinical diagnostics and product solutions, inclu… Read more